Investigational Drug Information for Narlaprevir

What is the drug development status for Narlaprevir?

Narlaprevir is an investigational drug.

There have been 7 clinical trials for Narlaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on May 7^th 2014.

The most common disease conditions in clinical trials are Hepatitis, Hepatitis C, Chronic, and Hepatitis C. The leading clinical trial sponsors are R-Pharm, Almedis, and Merck Sharp & Dohme Corp.

Summary for Narlaprevir

US Patents	0
International Patents	0
US Patent Applications	498
WIPO Patent Applications	177
Japanese Patent Applications	46
Clinical Trial Progress	Phase 3 (2014-05-07)
Vendors	33

Recent Clinical Trials for Narlaprevir

Title	Sponsor	Phase
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1	Almedis	Phase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1	ChromSystemsLab	Phase 2
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1	Scientific Center EFiS	Phase 2

See all Narlaprevir clinical trials

Clinical Trial Summary for Narlaprevir

Top disease conditions for Narlaprevir

Top clinical trial sponsors for Narlaprevir

See all Narlaprevir clinical trials

US Patents for Narlaprevir

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Narlaprevir Development Update and Market Projection

Last updated: September 24, 2026

Narlaprevir is a first-generation hepatitis C virus (HCV) NS3/4A protease inhibitor marketed in Russia as Ganovo. Its development reached regulatory approval, but the product has limited commercial relevance because it requires combination therapy, targets genotype 1 HCV, and competes with simpler pan-genotypic direct-acting antivirals (DAAs). Narlaprevir has no established U.S. or European Union approval, no meaningful global launch platform, and no identifiable biosimilar or generic challenge of commercial significance.

The commercial base case is a small, declining Russia-centered market. Estimated annual narlaprevir sales are likely in the low-single-digit to low-double-digit millions of U.S. dollars, with material downside if Russian procurement shifts further toward pan-genotypic regimens.

What is narlaprevir and how does it work?

Narlaprevir is an HCV NS3/4A serine protease inhibitor. It blocks proteolytic processing of the viral polyprotein, disrupting replication of HCV genotype 1.

Attribute	Narlaprevir
International nonproprietary name	Narlaprevir
Brand	Ganovo
Drug class	HCV NS3/4A protease inhibitor
Primary target	HCV NS3/4A protease
Initial target population	Chronic HCV genotype 1
Dosage form	Oral capsule
Strength	100 mg
Originator/commercial developer	R-Pharm, with development rights associated with Merck & Co.
Principal market	Russia
U.S. approval	No FDA approval identified
EU approval	No centralized EU approval identified
Current strategic position	Regional, legacy DAA product

Narlaprevir is administered with ritonavir as a pharmacokinetic enhancer and has historically been used with pegylated interferon and ribavirin. That treatment architecture is commercially disadvantaged against once-daily, interferon-free regimens with broad genotype coverage.

What is the development status of narlaprevir?

Narlaprevir completed clinical development for genotype 1 chronic HCV and received Russian regulatory approval in 2017. The registration program evaluated narlaprevir in combination with ritonavir, pegylated interferon alfa, and ribavirin.

A representative Russian development program was the PIONEER study, which evaluated narlaprevir-based therapy in treatment-naive patients with HCV genotype 1. The program supported regulatory filing and commercialization in Russia.

Key development milestones

Date	Milestone
2000s	Discovery and clinical development of narlaprevir as an HCV protease inhibitor
2010s	Russian clinical development, including narlaprevir plus ritonavir and pegylated interferon/ribavirin
2016-2017	Regulatory review and registration activity in Russia
2017	Russian approval and commercial launch of Ganovo
2018 onward	Commercial use constrained by newer interferon-free and pan-genotypic DAAs
2020s	No material evidence of expansion into the United States, European Union, or major high-income HCV markets

The product’s development is therefore complete for its established indication. No active late-stage global development program has emerged to reposition narlaprevir against modern pan-genotypic regimens.

What is the FDA regulatory status of narlaprevir?

Narlaprevir is not an FDA-approved HCV therapy. It does not have an FDA-approved label, an FDA Orange Book listing, or U.S. reference-product exclusivity.

No publicly material U.S. development program has produced a new drug application approval for narlaprevir. As a result:

• No U.S. commercial market exists for the branded product.
• No U.S. Paragraph IV litigation pathway is commercially relevant.
• No U.S. generic launch calendar is established.
• U.S. regulatory value is limited unless a new sponsor develops a differentiated regimen and files a new application.

The same distinction applies in the European Union, where narlaprevir has not become a broad regional HCV product.

What patents protect narlaprevir?

Publicly available information supports the existence of historical patent filings covering narlaprevir and related protease-inhibitor chemistry, formulations, combinations, and methods of treatment. The commercially important question is whether enforceable patent rights remain active in each jurisdiction.

A complete live-patent assessment requires jurisdiction-specific review of national registers, patent-family status, terminal disclaimers, supplementary protection certificates, annuity payments, and regulatory extensions. Based on the product’s development vintage and 2017 Russian approval, any original compound patent protection would generally be expected to face expiration or late-life status during the 2020s, depending on the earliest priority date and jurisdiction.

Patent categories relevant to narlaprevir

Patent category	Commercial relevance
Compound claims	Protect the active narlaprevir molecule or closely related chemical matter
Salt and crystalline-form claims	May protect specific solid-state forms used in manufacturing
Pharmaceutical-composition claims	May cover capsule formulations and excipient combinations
Combination claims	May cover narlaprevir with ritonavir, interferon, or ribavirin
Method-of-use claims	May cover treatment of genotype 1 HCV
Manufacturing claims	May create process barriers if the active ingredient is difficult to synthesize
Regional rights	Determine whether protection survives in Russia, CIS markets, Europe, or other territories

No reliable public evidence establishes a broad, enforceable, global narlaprevir patent moat comparable to the estates that protected major first-wave HCV products such as sofosbuvir, ledipasvir, or grazoprevir.

When does narlaprevir lose exclusivity?

Narlaprevir’s regulatory exclusivity has already ceased to be a meaningful commercial barrier in its principal market. Russia’s approval occurred in 2017, and the product is not protected by U.S. or EU regulatory exclusivity.

Patent expiry depends on the individual family. For a conventional 20-year term, relevant patents would generally expire approximately 20 years after their earliest nonprovisional priority or filing date, subject to national rules and possible patent-term adjustments. Historical HCV protease-inhibitor filings from the 2000s would ordinarily reach the end of their life during the 2020s.

The practical loss of exclusivity occurred earlier than a formal patent-expiry date because treatment guidelines and prescribing behavior shifted toward newer DAAs with:

• Pan-genotypic activity
• Shorter treatment courses
• No interferon requirement
• Fewer drug interactions
• Higher tolerability
• Stronger clinical and procurement support

Are there Paragraph IV challenges or generic competitors?

No material U.S. Paragraph IV challenge is associated with narlaprevir because the product lacks an FDA-approved reference product. There is no established U.S. generic filing or launch scenario.

In Russia and other non-U.S. markets, local competition may arise through national registration, procurement substitution, or alternative HCV products rather than the U.S. Hatch-Waxman Paragraph IV process. The main competitive threat is not a direct narlaprevir generic. It is therapeutic substitution by pan-genotypic DAAs.

Potential substitutes include:

Product	Competitive effect
Sofosbuvir-based regimens	Broad genotype coverage and extensive global use
Sofosbuvir/velpatasvir	Pan-genotypic positioning and interferon-free therapy
Glecaprevir/pibrentasvir	Short-course pan-genotypic treatment
Elbasvir/grazoprevir	Direct competitor in genotype 1 and selected populations
Other local DAA combinations	Price-driven substitution in government tenders

What is the Orange Book status of narlaprevir?

Narlaprevir has no Orange Book status because it has no FDA-approved reference listing. No U.S. patents are listed against an FDA reference product, and no U.S. authorized generic or 505(b)(2) pathway is commercially visible.

This sharply limits the value of U.S. formulation, method-of-use, or combination patents. Any remaining rights have greater relevance in Russia, selected CIS jurisdictions, or private-label supply arrangements than in the U.S. market.

How strong is the narlaprevir patent estate?

The patent estate is commercially weak on a global basis and potentially moderate for selected regional manufacturing or formulation rights.

Strength assessment

Factor	Assessment
Compound protection	Likely late-life or expired in several jurisdictions
Regulatory exclusivity	Not commercially relevant outside Russia
Formulation protection	Potentially useful but unlikely to block modern DAA substitution
Method-of-use protection	Narrow because the product is associated primarily with genotype 1
Manufacturing barriers	Possible, but not demonstrated to create a durable global moat
Geographic breadth	Concentrated in Russia and related markets
Litigation leverage	Low based on the absence of major public litigation
Competitive durability	Low

Narlaprevir’s strongest residual protection, if any, is more likely to arise from local registration, supply arrangements, know-how, or manufacturing economics than from a broad international patent barrier.

What patent litigation and settlement agreements affect narlaprevir?

No major publicly reported patent litigation or settlement agreement has materially altered narlaprevir’s commercial position. There is no known U.S. litigation calendar involving a narlaprevir reference product, and no major global settlement has produced a structured generic-entry date.

The absence of litigation is consistent with the product’s limited market size and lack of U.S. approval. Patent disputes are more economically attractive around large global HCV products than around a Russia-centered protease inhibitor with declining demand.

What licensing deals supported narlaprevir?

Narlaprevir development was associated with collaboration and licensing arrangements involving R-Pharm and Merck & Co. The strategic rationale was to transfer and commercialize an HCV protease-inhibitor program in Russia and nearby markets.

The arrangement gave R-Pharm a regional development and commercialization platform. It did not produce a major global launch comparable to Merck’s broader HCV portfolio. Publicly available information does not indicate a later licensing transaction that expanded narlaprevir into the U.S., European Union, Japan, or other major DAA markets.

What is the market projection for narlaprevir?

Narlaprevir is best modeled as a declining regional product rather than a global growth asset.

Base-case projection, 2025-2030

Scenario	2025 estimated sales	2030 estimated sales	Key assumptions
Bear case	$0-$5 million	Below $2 million	Rapid procurement displacement and limited new starts
Base case	$5-$15 million	$2-$8 million	Continued Russian use in selected genotype 1 patients and price-sensitive channels
Upside case	$15-$30 million	$8-$15 million	Local procurement support, supply disruptions affecting alternatives, or expanded regional access

These are analyst estimates rather than reported company revenue. The estimate reflects the limited geographic footprint, declining genotype 1 treatment share, competition from pan-genotypic therapies, and the absence of a global regulatory platform.

Market drivers

Narlaprevir could retain a small commercial base where:

• Local guidelines continue to recognize the regimen.
• Government tenders prioritize domestic or regionally supplied products.
• Price discounts offset the regimen’s clinical disadvantages.
• Physicians treat genotype 1 patients already familiar with the product.
• Supply constraints affect competing DAAs.

Market risks

The principal risks are:

1. Replacement by pan-genotypic DAAs.
2. Reduced use of interferon-containing regimens.
3. Limited access to international clinical-development capital.
4. Patent expiry or local generic entry.
5. Procurement consolidation around lower-cost sofosbuvir-based products.
6. Supply-chain restrictions affecting imported active pharmaceutical ingredients or manufacturing inputs.
7. Declining untreated genotype 1 prevalence in the addressable market.

How does narlaprevir compare with competing HCV drugs?

Narlaprevir is disadvantaged on nearly every commercial dimension relative to current standard DAA combinations.

Metric	Narlaprevir	Modern pan-genotypic DAA
Genotype coverage	Primarily genotype 1	Broad or pan-genotypic
Interferon requirement	Historically associated with interferon-based therapy	Usually interferon-free
Treatment complexity	Higher	Lower
Drug interactions	Ritonavir-related interaction burden	Generally lower, regimen dependent
Global approvals	Limited	Broad
Current guideline position	Narrow or declining	Standard of care in many markets
Patent leverage	Regional and late-life	Varies, but historically stronger
Commercial outlook	Declining niche	Larger remaining treatment market

What is the generic launch risk for narlaprevir?

The direct generic-launch risk is moderate in Russia and low in the United States because the U.S. product is not approved. The larger risk is indirect substitution.

A direct generic could reduce price and expand access in Russia, but lower price would not solve the product’s clinical disadvantages. Generic competition is therefore more likely to accelerate revenue erosion than to create a large new market.

The most probable commercial outcome is gradual contraction, with residual sales sustained by local procurement, physician familiarity, and price-sensitive treatment channels.

Key Takeaways

• Narlaprevir is a Russian-approved HCV NS3/4A protease inhibitor marketed as Ganovo.
• Its development program is complete, with no material global expansion evident.
• The product has no FDA approval, no Orange Book listing, and no meaningful U.S. Paragraph IV exposure.
• Its primary competitive problem is therapeutic obsolescence, not a single direct generic challenger.
• Patent value is likely regional and late-life, with possible residual relevance for formulations, combinations, and manufacturing.
• The 2025 base-case market estimate is approximately $5 million to $15 million annually.
• Base-case sales are projected to decline to approximately $2 million to $8 million by 2030.
• The asset is commercially more suitable for regional supply, licensing, or low-cost procurement strategies than for global pharmaceutical investment.

FAQs

Is narlaprevir still being developed?

No major global late-stage development program is publicly associated with narlaprevir. Its principal development objective was achieved through Russian approval and commercialization.

Is Ganovo the same as narlaprevir?

Yes. Ganovo is the Russian brand name associated with narlaprevir.

Can narlaprevir compete with sofosbuvir?

Only in narrow, price-sensitive settings. Sofosbuvir-based regimens generally have broader genotype coverage, simpler administration, and stronger international guideline support.

Does narlaprevir have biosimilar risk?

No conventional biosimilar risk applies because narlaprevir is a small-molecule drug. The relevant threat is generic or multisource small-molecule competition.

Is narlaprevir available in the United States?

Narlaprevir does not have an established FDA-approved commercial product in the United States.

References

1. ClinicalTrials.gov. (n.d.). Clinical studies of narlaprevir in chronic hepatitis C. U.S. National Library of Medicine.

2. European Medicines Agency. (n.d.). Direct-acting antiviral medicines for chronic hepatitis C. European Medicines Agency.

3. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. R-Pharm. (n.d.). Narlaprevir and Ganovo product information. R-Pharm.

5. World Health Organization. (2024). Global hepatitis report 2024. World Health Organization.

6. European Association for the Study of the Liver. (2020). EASL recommendations on treatment of hepatitis C. Journal of Hepatology, 73(5), 1170-1218.